A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

Condition:   Carcinoma, Squamous Cell Interventions:   Drug: A317;   Drug: VTX-2337 Sponsor:   Celgene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials